0
₹0 0
Nextgen Biotech

Call us:

menu

Nab Paclitero 100mg - Paclitaxel Injections

  • Home
  • Nab Paclitero 100mg - Paclitaxel Injections

Nab Paclitero 100mg - Paclitaxel Injections

Nab Paclitero 100mg is an albumin-bound formulation of Paclitaxel used in the treatment of advanced cancers like breast, lung, and pancreatic cancer. Its novel formulation allows for better solubility and reduced hypersensitivity reactions compared to conventional Paclitaxel.

Select the packing Size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Nab-Paclitaxel (Albumin-bound Paclitaxel)
Brand Name: Nab Paclitero 100mg
Packing: Single-dose vial
Strength: 100 mg/vial
Manufacturer: [Insert Manufacturer Name]
Form: Lyophilized powder for reconstitution or suspension for infusion
Category: Antineoplastic Agent – Taxane derivative (nanoparticle formulation)
Product Introduction:
Nab Paclitero 100mg contains Paclitaxel bound to human albumin nanoparticles (nanoparticle albumin-bound or nab-paclitaxel). Unlike traditional Paclitaxel, it does not require solvents like Cremophor EL, making it safer and reducing the need for pre-medications. It is administered intravenously and is especially favored in patients with prior hypersensitivity to solvent-based taxanes.
Uses:
Nab Paclitero 100mg is indicated for the treatment of:
  1. Metastatic breast cancer (after failure of combination chemotherapy)
  2. Non-small cell lung cancer (NSCLC) (in combination with carboplatin)
  3. Metastatic pancreatic cancer (in combination with gemcitabine)
  4. Off-label use in other solid tumors where taxanes are indicated
  5. Considered in patients intolerant to Cremophor EL-based Paclitaxel
Storage Instructions:
  1. Store below 25°C
  2. Protect from light and moisture
  3. Do not freeze
  4. Use immediately after reconstitution or as per institutional guidelines
  5. Keep out of reach of children
How It Works (Mechanism of Action):
Paclitaxel binds to the β-subunit of tubulin, promoting microtubule polymerization and inhibiting their disassembly. This leads to mitotic arrest and apoptosis in rapidly dividing cancer cells. The albumin-bound formulation enhances drug delivery via gp60-mediated endothelial transcytosis and SPARC (secreted protein acidic and rich in cysteine) interaction in tumor tissues.
Side Effects:
Common side effects:
  1. Neutropenia (low white blood cells)
  2. Anemia
  3. Peripheral neuropathy
  4. Fatigue
  5. Nausea and vomiting
  6. Diarrhea
  7. Alopecia (hair loss)
Severe side effects:
  1. Severe bone marrow suppression
  2. Liver enzyme elevations
  3. Severe hypersensitivity (rare with nab formulation)
  4. Cardiac abnormalities (rare)
  5. Infections due to immunosuppression
Dosage (Typical Recommended Dose):
  1. For metastatic breast cancer: 260 mg/m² IV over 30 minutes every 3 weeks
  2. For NSCLC: 100 mg/m² IV on days 1, 8, and 15 of each 21-day cycle (with carboplatin)
  3. For pancreatic cancer: 125 mg/m² IV on days 1, 8, and 15 (with gemcitabine)
  4. Dose adjustments based on body surface area (BSA), response, and toxicity
Method of Administration:
  1. Administered via intravenous infusion over 30 minutes
  2. No pre-medication required for hypersensitivity prevention
  3. Reconstitute with sterile water or as per the manufacturer’s instruction
  4. Given under strict medical supervision in oncology settings
Precautions:
  1. Monitor CBC, liver function, and renal function regularly
  2. Use effective contraception during and for several months after treatment
  3. Avoid in pregnancy and breastfeeding
  4. Patients with severe neuropathy or hepatic impairment require close monitoring or dose adjustments
  5. Watch for signs of infection, bleeding, or allergic reactions
Drug Interactions:
  1. Metabolized by CYP2C8 and CYP3A4 – avoid concurrent strong inhibitors or inducers
  2. Co-administration with gemcitabine or carboplatin increases myelosuppression risk
  3. Avoid live vaccines
  4. Report all medications, including over-the-counter and herbal products, to your oncologist
Allergies:
  1. Hypersensitivity reactions are rare with the nab-formulation but possible
  2. Contains no Cremophor EL, reducing allergy risks compared to conventional Paclitaxel
  3. Patients with albumin (human) allergy should use with caution
Overdose Information:
  1. Symptoms: Severe bone marrow suppression, neuropathy, mucositis
  2. No specific antidote
  3. Supportive care includes growth factors, hydration, and infection management in an intensive care setting
Missed Dose Instructions:
  1. Inform your healthcare provider as soon as possible
  2. Missed doses are rescheduled based on patient’s lab reports and clinical status
  3. Do not self-administer or attempt to double dose
Additional Notes:
  1. Hair loss is expected but temporary
  2. Neuropathy may be dose-limiting—report early signs like tingling or numbness
  3. Maintain a nutritious diet and hydration during treatment
  4. This formulation is preferred in patients with hypersensitivity to conventional taxanes
  5. Regular blood tests and physical assessments are vital for safe treatment

In The Same Category

Cart